Raymond James upgrades Liquidia stock rating on Yutrepia strength
Raymond James upgraded Liquidia Technologies (LQDA) to Strong Buy, raising its price target to $77 from $53. The company's Yutrepia product showed strong sales, with $227.7M in Q3 2026 product sales and a 92.5% gross profit margin. LQDA reported Q3 revenue of $225.3M, beating estimates, driven by Yutrepia's 31% quarterly sales growth. Analysts have mixed but generally positive outlooks on LQDA's future performance.
How this was made
The 30-second read
Why it matters
The upgrade reflects confidence in product uptake despite the loss, indicating a net positive outlook.
Market read
Analyst upgrade and earnings beat provide a fresh catalyst for Liquidia, likely prompting short-term buying interest.
What to watch
Potential volatility as Yutrepia label stabilizes and legal settlement finalization remains pending.
Background
Liquidia reported Q3 revenue of $225.3M, beating forecasts, driven by Yutrepia sales, but posted a GAAP loss due to a $389.7M settlement charge.
Ticker impact
Raymond James upgraded Liquidia Technologies to Strong Buy and raised the price target to $77, citing strong Yutrepia sales and Q3 revenue beat.
likely upward pressure as investors price in the new target and sales growth
Analyst upgrade with a 50% target increase is a concrete catalyst that can move the stock in the short term.
Market effects
Positive signal for biotech/rare disease space, may lift peers with inhaled therapies.
U.S. biotech sector could see modest gains.
Limited to investors tracking US biotech equities.
Counterpoint
The settlement charge and GAAP loss could weigh on margins, suggesting caution.
Key entities
- companyLiquidia Technologies
Biotech firm developing inhaled therapies.
- analystRaymond James
Upgraded Liquidia to Strong Buy.
